Eupatilin
(Synonyms: 异泽兰黄素) 目录号 : GN10511
Eupatilin是一种具有多种生物活性的天然黄酮类化合物,是过氧化物酶体增殖物激活受体α(PPARα)的激动剂,具有抗凋亡,抗氧化,及抗炎等功效。
Cas No.:22368-21-4
Sample solution is provided at 25 µL, 10mM.
Eupatilin is a natural flavonoid compound with multiple biological activities. It is an agonist of peroxisome proliferator-activated receptor α (PPARα) and has anti-apoptotic, antioxidant, and anti-inflammatory effects[1, 2]. Eupatilin has a significant effect in inhibiting tumor growth and can be used in cancer research[3].
In vitro, pretreatment of retinal pigment epithelial (RPE) cells (ARPE-19 cells) with Eupatilin (10, 25, 50μM) for 24h reduced the generation of intracellular ROS induced by H2O2 in a dose-dependent manner, upregulated the expression of Bcl-2 and the phosphorylation levels of PI3K and Akt, downregulated the expression of Bax, and inhibited the activity of caspase-3[4]. Eupatilin (0-400µg/mL) treated osteosarcoma U-2 cells for 96h inhibited cell growth in a dose- and time-dependent manner, changed cell cycle distribution, induced cell apoptosis, induced mitochondrial dysfunction and cytochrome c release[5]. Eupatilin (0-100μM) treated human endometrial cancer cell lines (Hec1A and KLE cells) for 96h significantly inhibited cell viability, was more effective than cisplatin, and induced cell cycle G2/M phase arrest[6].
In vivo, oral treatment of mice treated with transient middle cerebral artery occlusion/reperfusion (tMCAO) surgery with Eupatilin (10mg/kg) significantly reduced cerebral infarction and improved neurological function in tMCAO-challenged mice[7]. Oral treatment of mice with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease (PD) with Eupatilin (10mg/kg) for 6 days improved the mice's motor deficits and reduced neuronal loss, inhibiting neuroinflammation and apoptosis[8].
References:
[1] Zeng J, Bao T, Yang K, et al. The mechanism of microglia-mediated immune inflammation in ischemic stroke and the role of natural botanical components in regulating microglia: A review[J]. Frontiers in immunology, 2023, 13: 1047550.
[2] Mavrogonatou E, Kletsas D. Plant-Derived Senotherapeutics for the Prevention and Treatment of Intervertebral Disc Degeneration and Aging[J]. Metabolites, 2024, 14(3): 146.
[3] Wang Y, Hou H, Li M, et al. Anticancer effect of eupatilin on glioma cells through inhibition of the Notch-1 signaling pathway[J]. Molecular Medicine Reports, 2016, 13(2): 1141-1146.
[4] Du L, Chen J, Xing Y. Eupatilin prevents H2O2-induced oxidative stress and apoptosis in human retinal pigment epithelial cells[J]. Biomedicine & Pharmacotherapy, 2017, 85: 136-140.
[5] Li Y Y, Wu H, Dong Y G, et al. Application of eupatilin in the treatment of osteosarcoma[J]. Oncology Letters, 2015, 10(4): 2505-2510.
[6] Cho J H, Lee J G, Yang Y I, et al. Eupatilin, a dietary flavonoid, induces G2/M cell cycle arrest in human endometrial cancer cells[J]. Food and Chemical Toxicology, 2011, 49(8): 1737-1744.
[7] Sapkota A, Gaire B P, Cho K S, et al. Eupatilin exerts neuroprotective effects in mice with transient focal cerebral ischemia by reducing microglial activation[J]. PLoS One, 2017, 12(2): e0171479.
[8] Zhang Y, Qin L, Xie J, et al. Eupatilin prevents behavioral deficits and dopaminergic neuron degeneration in a Parkinson's disease mouse model[J]. Life sciences, 2020, 253: 117745.
Eupatilin是一种具有多种生物活性的天然黄酮类化合物,是过氧化物酶体增殖物激活受体α(PPARα)的激动剂,具有抗凋亡,抗氧化,及抗炎等功效[1, 2]。Eupatilin在抑制肿瘤生长方面具有显著效果,能够用于癌症研究[3]。
在体外,Eupatilin(10, 25, 50μM)预处理视网膜色素上皮(RPE)细胞(ARPE-19细胞)24h,以剂量依赖性方式减少了H2O2诱导的细胞内ROS的生成,上调了Bcl-2的表达和PI3K、Akt的磷酸化水平,下调了Bax的表达,抑制了caspase-3的活性[4]。Eupatilin(0-400µg/mL)处理骨肉瘤U-2细胞96h,以剂量和时间依赖性方式抑制了细胞的生长,改变了细胞周期分布,诱导了细胞凋亡,诱导了线粒体功能障碍和细胞色素c释放[5]。Eupatilin(0-100μM)处理人子宫内膜癌细胞系(Hec1A和KLE细胞)96h,显著抑制了细胞活力,比顺铂更有效,诱导了细胞周期G2/M期停滞[6]。
在体内,Eupatilin(10mg/kg)通过口服治疗暂时性大脑中动脉闭塞/再灌注 (tMCAO)手术处理的小鼠,显著减少了脑梗塞并改善tMCAO攻击小鼠的神经功能[7]。Eupatilin(10mg/kg)通过口服治疗1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)诱发的帕金森(PD)小鼠6天,改善了小鼠的运动缺陷和,减少了神经元丢失,抑制了神经炎症和细胞凋亡[8]。
Cell experiment [1]: | |
Cell lines | ARPE-19 cells |
Preparation Method | After reaching 80% confluence, ARPE-19 cells were seeded at a density of 1×105 cells/well in 96-well culture plates and then incubated with different concentrations of Eupatilin (10, 25, and 50μM). Subsequently, the medium was removed, and the cells were exposed to 500μM H2O2 for 24h. The production of ROS was detected by DCFH-DA. |
Reaction Conditions | 10, 25, 50μM; 24h |
Applications | Pretreatment with Eupatilin obviously inhibited ROS production in a dose-dependent manner. |
Animal experiment [2]: | |
Animal models | Male ICR mice |
Preparation Method | Mice that were challenged with transient middle cerebral artery occlusion/reperfusion (tMCAO) were randomly divided into the vehicle-treated, the Eupatilin-treated, or the Edaravone-treated groups. Eupatilin or Edaravone was dissolved in 10% Tween 80 (vehicle). Each group was administered vehicle (10% Tween 80, p.o.), Eupatilin (1, 3, 10mg/kg, p.o.), or Edaravone (3mg/kg, p.o.) immediately after reperfusion. Alternatively, Eupatilin (10mg/kg) was orally administered to mice 5h after MCAO induction. After tMCAO challenge, mice were housed 3 per cage with moist food and soft bedding materials to reduce suffering. Mice were monitored by visual inspection and body weight measurement every 12h following tMCAO till the experimental endpoints. |
Dosage form | 10mg/kg; p.o. |
Applications | Oral administration of Eupatilin (10mg/kg) in a therapeutic paradigm significantly reduced brain infarction and improved neurological functions in tMCAO-challenged mice. |
References: |
Cas No. | 22368-21-4 | SDF | |
别名 | 异泽兰黄素 | ||
化学名 | 2-(3,4-dimethoxyphenyl)-5,7-dihydroxy-6-methoxychromen-4-one | ||
Canonical SMILES | COC1=C(C=C(C=C1)C2=CC(=O)C3=C(C(=C(C=C3O2)O)OC)O)OC | ||
分子式 | C18H16O7 | 分子量 | 344.32 |
溶解度 | ≥ 34.4mg/mL in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 2.9043 mL | 14.5214 mL | 29.0428 mL |
5 mM | 0.5809 mL | 2.9043 mL | 5.8086 mL |
10 mM | 0.2904 mL | 1.4521 mL | 2.9043 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet